MSA Safety Reports 1st Elastomeric Respirator Without Exhalation Valve Is Approved by NIOSH

November 25, 2020

MSA Safety today reported that its next-generation Advantage 290 LS Air-Purifying Respirator (APR) is the first of its kind — designed without an exhalation valve — to receive approval from the National Institute for Occupational Safety and Health (NIOSH).

MSA Safety notes an elastomeric half-mask device, the Advantage 290 LS Respirator covers a wearer’s nose and mouth and utilizes twin filters to provide respiratory protection.

The U.S. Centers for Disease Control and Prevention (CDC) advises that NIOSH-approved respirators, including elastomeric half-mask respirators (EHMRs), are appropriate for use against SARS-CoV-2 in healthcare settings.  This established class of respirator can play a critical role in the nation’s response to COVID-19 and, importantly, bolster future readiness for similar microbial viruses and other emergencies.

In response to the global shortage of personal protective equipment (PPE), MSA has been working throughout the year with healthcare professionals to identify the respiratory protection needs of those on the front line of the pandemic.  Some applications within healthcare require a sterile environment, and one critical component to ensuring a sterile environment is source control. The Advantage 290 Respirator is the first EHMR to function without an exhalation valve, making it a new respiratory protection option that provides both personal protection and source control.  In addition, the new respirator gives healthcare facilities greater optionality and flexibility in developing their respiratory protection programs in accordance with Occupational Safety and Health Administration standards.

“Given the reusable design and nature of elastomeric respirators, there are many benefits of deploying a respiratory protection program that incorporates EHMRs, including cost-efficiency, reduced space requirements for PPE warehousing, and fewer concerns associated with PPE insecurities during a pandemic,” said Greg Martin, MSA Vice President of Product Strategy and Development.

Mr. Martin added that EHMRs also help mitigate concerns about product expiration while conferring additional benefits, like environmental sustainability, through extended use and reuse capability. “With the Advantage 290 model, our team went a step further and developed a respirator that has the potential to be an even more appealing option – today and down the road – for healthcare systems everywhere as they assess plans for the future and their own pandemic preparedness,” he said.

The Advantage 290 Respirator, which will be available for preorder in December 2020, will be produced at MSA Safety’s subsidiary operation in Jacksonville, N.C.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

The Evolut ™ FX+ TAVR system leverages market-leading valve performance with addition of larger windows to facilitate coronary access
The study was an analysis of AstraZeneca’s Phase 2 52-Week clinical trial of tralokinumab in patients with Idiopathic Pulmonary Fibrosis (IPF). The patient data from the trial was processed with Brainomix’s e-Lung tool. The tool is uniquely powered by the weighted reticulovascular score (WRVS), a novel biomarker that incorporates reticular opacities and vascular structures of the lung.
“Since the algorithm for matching patients with donors is changing across for all organs, this was a prime time to better understand whether transplant team decisions to accept a donated organ varied by patient race and gender,” she said. “We wanted to understand how the process of receiving a transplant after listing varied by race and gender, and the combination of the two, so that steps can be taken to make that process more equitable," said Khadijah Breathett, MD.
The Mount Sinai study found that primary care physicians’ approach reflects a dearth of evidence-based guidance for lung cancer screening shared decision-making in patients with complex comorbidities
This is the first ever transplantation of a genetically engineered porcine kidney into a living human recipient.

By using this website you agree to accept Medical Device News Magazine Privacy Policy

Exit mobile version